These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332 [TBL] [Abstract][Full Text] [Related]
3. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642 [TBL] [Abstract][Full Text] [Related]
4. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. Daaboul N; Nicholas G; Laurie SA Curr Oncol; 2018 Jun; 25(Suppl 1):S77-S85. PubMed ID: 29910650 [TBL] [Abstract][Full Text] [Related]
5. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Sgambato A; Casaluce F; Maione P; Gridelli C Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012 [TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116 [TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
9. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Shea M; Costa DB; Rangachari D Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497 [TBL] [Abstract][Full Text] [Related]
10. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era? Ou SH; Soo RA Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839 [TBL] [Abstract][Full Text] [Related]
11. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500 [TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Horn L; Bauml J; Forde PM; Davis KL; Myall NJ; Sasane M; Dalal A; Culver K; Wozniak AJ; Baik CS; Mutebi A; Zhang P; Wakelee HA; Johnson BE Lung Cancer; 2019 Feb; 128():74-90. PubMed ID: 30642457 [TBL] [Abstract][Full Text] [Related]
13. Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact Durbin L; Murali B; Li S; Hawthorne S; Clark O Future Oncol; 2024; 20(19):1319-1331. PubMed ID: 38695478 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950 [TBL] [Abstract][Full Text] [Related]